Table 4 Opportunities and challenges
| Strengths/opportunities | Challenges | Recommendations | |
|---|---|---|---|
| Utility |
Transparency Adaptability to local priorities/needs Participatory and multi-stakeholder approach Consideration of trade-offs (price vs. quality + non-quality criteria) |
Requires replacement of current process Need for evidence to prove the MCDA effectiveness Perception of complexity in implementation Requires more time and work than price-only decisions |
Create full transparency Involve broadly throughout process Support and reinforce new behaviour Measure success |
| Methodology |
Consistent/systematic decision approach Process quality assurance Flexibility (e.g., different value frameworks for different drug classes) Pragmatic, user-oriented, and modular |
Criteria selection, validation, and measurement; improve applicability for users Criteria definitions need to be more precise |
Ensure fit of criteria in evaluation setting Detailed guidance on criteria and scoring |
| Data requirements | Adaptable to local data |
Data retrieval and synthesis by criteria Data interpretation | Detailed guidance on data requirements |
| Capacity/training requirements | Upskilling of evaluating personnel |
Lack of training and knowledge Need for continuous re-enforcement |
Education on why Training on how Retrain |
| Broader societal impact | Criteria as requirements to be met by suppliers upskilling of suppliers | Threat perceived by local industry |
Guidance for manufacturers/suppliers Self-scoring tools Feed-back to suppliers Training for suppliers Full transparency |